Now showing items 1-3 of 3

    • Disease-modifying drugs for knee osteoarthritis: can they be cost-effective? 

      Losina, Elena; Daigle, Meghan E.; Reichmann, William M.; Suter, Lisa G.; Hunter, David J.; Solomon, Daniel H.; Walensky, Rochelle P.; Jordan, Joanne M.; Burbine, Sara A.; Patiel, A. Daniel; Katz, Jeffrey N. (Elsevier, 2013-05)
      OBJECTIVE: Disease-modifying osteoarthritis drugs (DMOADs) are under development. Our goal was to determine efficacy, toxicity, and cost thresholds under which DMOADs would be a cost-effective knee OA treatment. DESIGN: ...
    • Lifetime risk and age of diagnosis of symptomatic knee osteoarthritis in the US 

      Losina, Elena; Weinstein, Alexander M.; Reichmann, William M.; Burbine, Sara A.; Solomon, Daniel H.; Daigle, Meghan E.; Rome, Benjamin N.; Chen, Stephanie P.; Hunter, David J.; Suter, Lisa G.; Jordan, Joanne M.; Katz, Jeffrey N. (Willey, 2013-05)
      OBJECTIVE: To estimate the incidence and lifetime risk of diagnosed symptomatic knee osteoarthritis (OA) and the age at diagnosis of knee OA based on self-reports in the US population. METHODS: We estimated the incidence ...
    • The MeTeOR Trial (Meniscal Tear in Osteoarthritis Research): Rationale and design features 

      Katz, Jeffrey N.; Chaisson, Christine E; Cole, Brian; Guermazi, Ali; Hunter, David J.; Jones, Morgan; Levy, Bruce A; Mandi, Lisa A; Martin, Scott; Marx, Robert G; Safran-Norton, Clare; Roemer, Frank W.; Skoniecki, Debra; Solomon, Daniel H.; Spindler, Kurt P.; Wright, John; Wright, Rick W; Losina, Elena (Elsevier, 2012-11)
      This paper presents the rationale and design features of the MeTeOR Trial (Meniscal Tear in Osteoarthritis Research; Clinical Trials.gov NCT00597012). MeTeOR is an NIH-funded seven-center prospective randomized controlled ...